Payment overview · 2025
General Payments
$442.38
22 reported records · 9 companies
Healthcare provider profile · identity verified
Robert Walker
Allopathic & Osteopathic Physicians|Emergency Medicine · HAZLEHURST, MS · NPI 1649216680
Verified facts
What the public records show
CMS Open Payments records show Robert Walker received $442.38 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $170.74 | 38.6% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $90.30 | 20.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.93 | 12.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.45 | 8.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.36 | 5.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.13 | 4.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.43 | 3.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.29 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.75 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $442.38 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.64 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.30 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.93 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.10 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.45 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 139 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
137 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 705 | 163 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 631 | 126 |
| Gabapentin | Gabapentin | 538 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 508 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 475 | 118 |
| Omeprazole | Omeprazole | 446 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 346 | 109 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 320 | 44 |
| Furosemide | Furosemide | 319 | 76 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 304 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 295 | 70 |
| Potassium Chloride | Potassium Chloride | 272 | 46 |
| Alprazolam | Alprazolam | 270 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 56 |
| Carvedilol | Carvedilol | 248 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 49 |
| Lisinopril | Lisinopril | 242 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 241 | 72 |
| Metformin Hcl | Metformin Hcl | 241 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 241 | 46 |
| Meloxicam | Meloxicam | 233 | 59 |
| Tramadol Hcl | Tramadol Hcl | 226 | 59 |
| Ibuprofen | Ibuprofen | 225 | 66 |
| Montelukast Sodium | Montelukast Sodium | 218 | 42 |
| Eliquis | Apixaban | 213 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 207 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 53 |
| Losartan Potassium | Losartan Potassium | 185 | 39 |
| Nabumetone | Nabumetone | 179 | 48 |
| Amitriptyline Hcl | Amitriptyline Hcl | 172 | 37 |
| Pregabalin | Pregabalin | 169 | 38 |
| Glimepiride | Glimepiride | 160 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 38 |
| Simvastatin | Simvastatin | 154 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 28 |
| Cefuroxime | Cefuroxime Axetil | 139 | 112 |
| Jardiance | Empagliflozin | 139 | 28 |
| Linzess | Linaclotide | 137 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 31 |
| Allopurinol | Allopurinol | 129 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 121 | 27 |
| Trazodone Hcl | Trazodone Hcl | 118 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 30 |
| Clonazepam | Clonazepam | 111 | 19 |
| Januvia | Sitagliptin Phosphate | 109 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | 16 |
| Famotidine | Famotidine | 99 | 24 |
| Atenolol | Atenolol | 98 | 22 |
| Sertraline Hcl | Sertraline Hcl | 96 | 18 |
| Donepezil Hcl | Donepezil Hcl | 92 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 13 |
| Nifedipine Er | Nifedipine | 91 | 23 |
| Valsartan | Valsartan | 91 | 23 |
| Buspirone Hcl | Buspirone Hcl | 84 | 15 |
| Mirtazapine | Mirtazapine | 84 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 15 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 81 | 27 |
| Baclofen | Baclofen | 80 | 15 |
| Diazepam | Diazepam | 78 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 17 |
| Celecoxib | Celecoxib | 70 | 18 |
| Spironolactone | Spironolactone | 70 | 19 |
| Clonidine Hcl | Clonidine Hcl | 68 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 68 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 67 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 15 |
| Sucralfate | Sucralfate | 65 | 17 |
| Bupropion Xl | Bupropion Hcl | 64 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 30 |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Trulicity | Dulaglutide | 62 | suppressed |
| Aripiprazole | Aripiprazole | 61 | 12 |
| Fenofibrate | Fenofibrate | 61 | 15 |
| Lorazepam | Lorazepam | 59 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | suppressed |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Naproxen | Naproxen | 54 | 18 |
| Ozempic | Semaglutide | 53 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 44 |
| Mupirocin | Mupirocin | 51 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | suppressed |
| Fluconazole | Fluconazole | 49 | 31 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 48 | 16 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 34 |
| Methylprednisolone | Methylprednisolone | 46 | 40 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Lansoprazole | Lansoprazole | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 30 |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | 11 |
| Temazepam | Temazepam | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 15 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 29 |
| Estradiol | Estradiol | 35 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 35 | 25 |
| Ibu | Ibuprofen | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Droplet Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 24 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Colchicine | Colchicine | 30 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Haloperidol | Haloperidol | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Glyburide Micronized | Glyburide,micronized | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Quinine Sulfate | Quinine Sulfate | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Tranexamic Acid | Tranexamic Acid | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $442.38 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, ENTRESTO, GEMTESA, JARDIANCE, LEQVIO, MOUNJARO, Ozempic, REXULTI, Rybelsus, VRAYLAR, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error